Arundic Acid ( DrugBank: Arundic acid )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症10

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004723-37-DE
(EUCTR)
16/05/200829/01/2008A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co., Ltd.NULLNot RecruitingFemale: yes
Male: yes
273Phase 2United Kingdom;Germany;Belgium;France
2EUCTR2007-004723-37-GB
(EUCTR)
12/05/200815/02/2008A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co., Ltd.NULLNot RecruitingFemale: yes
Male: yes
273Phase 2Germany;United Kingdom;Belgium;France
3EUCTR2007-004723-37-BE
(EUCTR)
23/04/200831/01/2008A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co., Ltd.NULLNot RecruitingFemale: yes
Male: yes
273Phase 2United Kingdom;Germany;Belgium;France
4EUCTR2007-004723-37-FR
(EUCTR)
15/04/200806/02/2008A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co., Ltd.NULLNot RecruitingFemale: yes
Male: yes
273Phase 2France;Belgium;Germany;United Kingdom
5EUCTR2006-002660-26-NL
(EUCTR)
17/04/200703/01/2007A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria
6EUCTR2006-002660-26-GB
(EUCTR)
08/01/200720/09/2006A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria
7EUCTR2006-002660-26-DE
(EUCTR)
20/12/200619/01/2007A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392United Kingdom;Germany;Netherlands;Belgium;France;Italy;Austria
8EUCTR2006-002660-26-FR
(EUCTR)
12/12/200610/10/2006A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392Phase 2France;Belgium;Austria;Germany;Netherlands;Italy;United Kingdom
9EUCTR2006-002660-26-AT
(EUCTR)
13/11/200606/11/2006A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria
10EUCTR2006-002660-26-BE
(EUCTR)
13/11/200628/09/2006A MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATIONA MULTI-CENTRE,RANDOMISED,DOUBLE BLIND,PLACEBO CONTROLLED,PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO,IN THE PRESENCE OF RILUZOLE,TO PATIENTS DIAGNOSED WITH AMYOTROPHIC LATERAL SCLEROSIS(ALS), WHO HAVE HAD ONSET OF MUSCLE WEAKNESS WITHIN 14 MONTHS OF RANDOMISATION Amyotrophic Lateral Sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Product Name: ONO-2506PO
Product Code: ONO-2506PO
INN or Proposed INN: Arundic Acid
Other descriptive name: (2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co.,LtdNULLNot RecruitingFemale: yes
Male: yes
392Germany;United Kingdom;Netherlands;Belgium;France;Italy;Austria